Evogene Ltd. (EVGN.TA)
- Previous Close
424.20 - Open
450.00 - Bid 364.00 x 286700
- Ask 366.60 x 100
- Day's Range
418.00 - 458.10 - 52 Week Range
357.30 - 2,989.00 - Volume
252,840 - Avg. Volume
21,963 - Market Cap (intraday)
28.732M - Beta (5Y Monthly) 1.18
- PE Ratio (TTM)
-- - EPS (TTM)
-10.66 - Earnings Date May 21, 2025 - May 26, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Evogene Ltd., together with its subsidiaries, operates as a computational biology company in Israel, the United States, Israel, Brazil, and internationally. The company focuses on product discovery and development in life-science based industries, including human health, agriculture, and other industrial applications through its computational predictive biology (CPB) platform. It operates through three segments: Agriculture, Human Health, and other Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, gastrointestinal inflammatory related disorders, and antimicrobial resistance organisms. The Industrial Applications segment focuses on the development and commercialization of improved castor bean seeds for industrial uses. The company also provides medical cannabis products. Evogene Ltd. was incorporated in 1999 and is headquartered in Rehovot, Israel.
www.evogene.comRecent News: EVGN.TA
View More
Performance Overview: EVGN.TA
Trailing total returns as of 4/22/2025, which may include dividends or other distributions. Benchmark is TA-125 (^TA125.TA) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EVGN.TA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EVGN.TA
View MoreValuation Measures
Market Cap
28.83M
Enterprise Value
19.84M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.77
Price/Book (mrq)
--
Enterprise Value/Revenue
0.63
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-193.69%
Return on Assets (ttm)
-30.52%
Return on Equity (ttm)
-82.96%
Revenue (ttm)
8.51M
Net Income Avi to Common (ttm)
-16.48M
Diluted EPS (ttm)
-10.66
Balance Sheet and Cash Flow
Total Cash (mrq)
15.31M
Total Debt/Equity (mrq)
16.87%
Levered Free Cash Flow (ttm)
-783.62k